Liver Fibrosis Market Forecast to 2034: Evolving Therapeutic Strategies Amid Rising Disease Burden | DelveInsight
Liver Fibrosis Market Forecast to 2034: Evolving Therapeutic Strategies Amid Rising Disease Burden | DelveInsight
Liver fibrosis is a progressive condition from chronic liver injury due to NASH, hepatitis B/C, alcoholic liver disease, and autoimmune hepatitis. Untreated, it leads to cirrhosis, liver failure, or HCC, often undiagnosed early due to silent progression.
DelveInsight’s “Liver Fibrosis – Market Insight, Epidemiology, and Market Forecast – 2034” analyzes the 7MM landscape, with epidemiological data by fibrosis stages (F0–F4), etiology, and diagnostics. It notes rising NASH-related fibrosis in aging, at-risk populations.
The market is transforming with better awareness, diagnostics (non-invasive imaging, biomarkers), and therapies. Current treatments target underlying causes; emerging ones halt or reverse fibrogenesis. REZDIFFRA (resmetirom) approval for MASH signals more antifibrotics.
By 2034, the market will grow significantly, driven by novel agents, screening, and R&D. The report covers dynamics, pipeline, unmet needs, and strategies.
Request a sample and uncover the latest breakthroughs shaping the Liver Fibrosis market landscape and future outlook
Key insights:
Emerging therapies: Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Lanifibranor (IVA337), Aramchol, WEGOVY (semaglutide 2.4 mg), VK2809, Rencofilstat (CRV431), Ervogastat + Clesacostat, Berberine ursodeoxycholate (HTD1801), Efimosfermin alfa, HU6, LPCN 1144, ALG-055009, MN-001 (tipelukast), Icosabutate, Tirzepatide (LY3298176).
Key companies: Inventiva Pharma, Galmed, Madrigal, Intercept, Galectin, Zydus, Axcella, Akero, Lipocine, Enyo, Sagimet, 89bio, HighTide, Rivus, Novo Nordisk. Japanese involvement includes Kowa (developing pemafibrate ER and FXR compounds for NASH/fibrosis metabolic pathways) and academic trials like PRI-724/OP-724 (Wnt-signaling inhibitor in Phase 1/2a for cirrhosis, showing tolerability and fibrosis signals). South Korea and Taiwan lack proprietary sponsors in Phase 1-3 fibrosis trials; Pfizer's Japan-based Phase 2 (PF-06865571 + PF-05221304) targets lipogenesis but is foreign-sponsored.
Curious for visuals? Check the liver fibrosis infographic here!
Liver Fibrosis Overview Liver fibrosis involves scar tissue buildup from chronic injury, often from NASH or hepatitis. Early detection is challenging, leading to advanced stages. Therapies now include antifibrotics and modulators, but reversal remains limited. Research focuses on early diagnosis and personalized treatments.
Epidemiology Trends in 7MM (2020–2034): Total diagnosed prevalent cases, severity-specific (F0–F4), and ≥F2 in MASH.
Drugs Uptake & Pipeline Analyzes adoption of new therapies, pipeline (e.g., GLP-1 agonists, FGF21 analogs, PPAR agonists, RNA interference, lipid inhibitors). Key developments: Academic Japanese trials (PRI-724) and foreign sponsors like Pfizer in Japan.
Get a free sample for the liver fibrosis market forecast, size & share analysis report: https://www.delveinsight.com/report-store/liver-fibrosis-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Market Outlook Transforming with direct antifibrotics like REZDIFFRA. Unmet needs: Reversal agents, better biomarkers. Pipeline momentum from Inventiva, Galmed, Novo Nordisk, etc.
Drivers: Rising NASH/obesity; approvals and novel agents.
Barriers: No reversal; poor diagnostics.
Scope: 2020–2034, 7MM. Companies/therapies as listed. Assessment: Marketed/emerging. Dynamics: Drivers/barriers. Analysis: SWOT, PESTLE, etc. Unmet needs, KOL views, access. (2,847 characters)
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Related report
Liver Fibrosis - Epidemiology Forecast - 2034
DelveInsight’s ‘Liver Fibrosis- Epidemiology Forecast–2034’ report delivers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The leading Liver Fibrosis Companies developing potential therapies include - Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Inventiva Pharma, Galmed Pharmaceuticals, Novo Nordisk A/S, Viking Therapeutics, Hepion Pharmaceuticals, Pfizer, HighTide Biopharma, Boston Pharmaceuticals, Rivus Pharmaceuticals, Lipocine, Aligos Therapeutics, MediciNova, NorthSea Therapeutics, Eli Lilly, and others.
Liver Fibrosis Pipeline Insight, 2025
DelveInsight’s, “Liver Fibrosis- Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Liver Fibrosis pipeline landscape. The leading Liver Fibrosis Companies developing potential therapies include - Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Inventiva Pharma, Galmed Pharmaceuticals, Novo Nordisk A/S, Viking Therapeutics, Hepion Pharmaceuticals, Pfizer, HighTide Biopharma, Boston Pharmaceuticals, Rivus Pharmaceuticals, Lipocine, Aligos Therapeutics, MediciNova, NorthSea Therapeutics, Eli Lilly, and others.
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com